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Abstract
Malaria continues to be an enormous global health challenge, with millions of new infections and deaths reported
annually. This is partly due to the development of resistance by the malaria parasite to the majority of established
anti-malarial drugs, a situation that continues to hamper attempts at controlling the disease. This has spurred
intensive drug discovery endeavours geared towards identifying novel, highly active anti-malarial drugs, and the
identification of quality leads from natural sources would greatly augment these efforts. The current reality is that
other than compounds that have their foundation in historic natural products, there are no other compounds in
drug discovery as part of lead optimization projects and preclinical development or further that have originated
from a natural product start-point in recent years. This paper briefly presents both classical as well as some more
modern, but underutilized, approaches that have been applied outside the field of malaria, and which could be
considered in enhancing the potential of natural products to provide or inspire the development of anti-malarial
lead compounds.
Background
Malaria remains the most devastating tropical disease,
with staggering infection and mortality statistics. The
WHO World Malaria Report 2008 estimated that there
were approximately 247 million malaria cases among 3.3
billion people at risk in 109 countries where malaria is
currently considered prevalent; 87% of these cases were
reported in the African region. The disease caused
nearly one million deaths, 91% of which were in Africa,
and 85% of these were of children under 5 years [1].
The main challenge to the effective management of
diagnosed malaria cases has been, and continues to be,
the resistance of the causative microorganisms to known
anti-malarials, which results in the non-resolution of
symptoms, recrudescence, and ultimately in treatment
failure [2-4].
Various strategies have been embraced in the fight
against malaria in general, and anti-malarial drug resis-
tance in particular, and include the improvement of pre-
scribing habits and therapeutic protocols, prevention of
infection and the use of combination therapies, with
particular emphasis being placed on artemisinin-based
combination therapy (ACT) [2,3,5-7]. In tandem with
these efforts has been the intensive drug discovery effort
aimed at developing new anti-malarial drugs or modify-
ing existing ones, and which targets the identification of
novel compounds that exhibit excellent experimental
and clinical anti-malarial efficacy without showing any
evidence of resistance. Unfortunately the current reality
is that other than compounds that have their foundation
in historic natural products (such as quinine, artemisi-
nin, hydroxynaphthoquinones, doxycyclin, clindamycin,
and azithromycin), there are no other compounds in
preclinical development or further that have originated
from a natural product start-point in recent years.
There are not even any compounds in current anti-
malarial lead optimization projects that have come from
natural products in recent years. Many natural products
have shown potent anti-plasmodial effects but, for a
variety of reasons, including chemical tractability issues,
these have not been pushed forward into hit-to-lead
drug discovery projects.* Correspondence: Kelly.Chibale@uct.ac.za
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Generic approaches to anti-malarial natural
product drug discovery
Nature is, as ever, an extremely rich source of potential
anti-malarial agents [8], with the anti-malarial drugs
quinine and artemisinin being outstanding examples of
therapeutic natural products [9,10].
Following the serendipitous or rational discovery of a
biologically active natural material, the conventional
approach to natural product development has been the
bioassay-guided fractionation of extracts derived from
such material, and the subsequent isolation and charac-
terization of pure, active compounds. With artemisinin
as an illustrative example (Figure 1) [9-12], the identifi-
cation of promising compounds in this way usually trig-
gers medicinal chemistry efforts geared towards the
total synthesis of the identified compounds and/or the
generation of analogs, and which are aimed at providing
a supplementary source of the product for further
study, revealing structure-activity relationships (SAR),
identifying more potent analogs and/or overcoming
challenging physicochemical and biological properties.
Using comparable approaches, the continuing search for
new anti-malarial drugs from natural sources has led to
the identification of an impressive range of structurally
diverse compounds from a variety of chemical classes
[9,13-15].
Challenges facing conventional natural product
drug discovery
The challenges facing conventional anti-malarial natural
product drug discovery (and indeed natural product
drug discovery in general) are many, and range from the
basic problems of reliable access and supply, seasonal or
environmental variations in the composition of living
organisms and loss of source through extinction or leg-
islation, to the more practical concerns associated with
the complexity of the mixtures after fractionation, the
isolation of very small quantities of bioactive substance
and challenging physicochemical properties such as
solubility and stability [16].
Part of the solution may be either to look for ways to
supplement the natural sources to meet the existing
demand of known bioactive molecules, or to consciously
widen the scope of the biodiversity that is sampled for
natural product drug discovery by, for example, the
exploration of extreme habitats not routinely considered
[17,18]. Recent advances in biotechnology and the
understanding of the genomics of natural product bio-
synthesis may enable the efficient production of the
same bioactive molecules from plant-cell cultures and
genetically engineered microorganisms [19], such as the
large-scale microbial production of the artemisinin pre-
cursors amorpha-4,11-diene and artemisinic acid from
genetically modified Saccharomyces cerevisiae and
Escherichia coli[20]. Sources that are known to be rich
in secondary molecules active against other diseases
could also be targeted as potential sources of anti-malar-
ial compounds. For example, the study of marine actino-
mycetes, long recognized as a rich source of secondary
metabolites with anticancer activity, yielded the highly
potent anti-malarial compound salinosporamide A
(Figure 1), isolated from the marine actinomycete Sali-
nispora tropica[21].
However, it is noteworthy that most anti-malarial
compounds isolated from natural sources are usually
only moderately active, or possess challenging physico-
chemical and biological properties, and as such repre-
sent ‘hits’ rather than actual lead drug candidates. It,
therefore, becomes apparent that considerable effort
needs to be made to complement conventional natural
product drug discovery and boost the chances of the
successful identification of quality lead compounds from
natural products, including their development from
naturally derived hits. Such efforts must include the
incorporation of what may be considered as more mod-
ern drug discovery strategies into anti-malarial natural
product drug discovery endeavors (Figure 2). This
would arguably increase the chances of successful iden-
tification and/or design of new potential leads, as well as
considerably enhance the range and depth of knowledge
and information that is derived from these discovery
efforts.
With past and recent examples, the potential of some
of these approaches is highlighted.
Drug combinations
As mentioned earlier, one of the strategies for evading
the development of resistance to anti-malarials is the
use of combination therapies, which basically involves
the co-administration of two or more anti-malarial
agents. Drugs selected for combination in this way
usually have a demonstrated synergistic effect when
applied together, thereby allowing for the use of lower
doses and achievement of more rapid therapeutic out-
comes while taking advantage of the lower risk of the
concurrent development of resistance by the microor-
ganism to the co-administered agents. Although the
emphasis is currently on artemisinin-based combination
therapy (ACT) [5-7], the identification of new and effi-
cacious combinations remains a priority, and the identi-
fication of new, active, naturally-derived compounds
could provide additional possibilities. The potential of
combinations of established anti-malarial drugs with
other bioactive compounds derived from natural sources
has already been demonstrated experimentally. For
example, the combination of chloroquine and a mixture
of febrifugine and isofebrifugine (isolated from the
leaves of Hydrangea macrophylla) was found to be more
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active in vivo than the individual components of the
combination [22].
Dual drugs
Dual drugs, also known as hybrid compounds, refer to
single chemical entities that consist of two drugs/active
compounds/pharmacophoric units linked together cova-
lently by a linker [23]. This aims to take advantage of
the observed (or anticipated) synergistic or additive
pharmacological activities of the hybrid components and
enable the identification of highly active novel chemical
entities. Highly active trioxaquines have been developed
by covalently linking a 1,2,4-trioxane motif (a peroxide
entity derived from the highly active natural sesquiter-
pene artemisinin) to a 4-aminoquinoline moiety (bor-
rowed from chloroquine and other chloroquinoline-
Artemisinin
O
O
O
O
H
H
H
O
FebǦA
N
N
N
H
O
HO
O
HO
N
N
N
H
O
O
HO
HO
IsofebǦA
N
N
N
H
O
HO
O
O
Areneoxidemetabolite
N
N
N
H
OHO
O
F
F
N
N
N
H
O
HO
OCF3
B
D
A
5
6
7
8
5
N N
N
O
O
N
H
HO
N
H
O O
O
HO
SalinosporamideA
NCl
N
H
H
N
H O O
O
Ph
Ph
2
N
H
NH
N
H
F
Cl
O
Cl
NTID609
C
Halofuginone
N
N
N
H
O
HO
O
Br
Cl
N
N
N
H
O
HO
O
N
N
N
H
O
HO
O
Cl
Cl
Cl
Cl
N
N
N
H
O
HO
O
Febrifugine
N
N
N
H
O
O
HO
Isofebrifugine
E
F
Figure 1 A: structure of artemisinin; B: salinosporamide A, an antimalarial compound isolated from marine actinomycetes; C: an example of a
highly active trioxaquine; D: febrifugine, isofebrifugine, metabolite feb-A and its synthetic analog isofeb-A, the arene oxide metabolite and
examples of potent but less hepatotoxic halogenated febrifugine analogs; E: Halofuginone, as well as some highly active febrifugine analogs
identified by virtual screening; F: NTID609, an extremely active and highly promising anti-malarial spiroindolone.
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based anti-malarials) via an appropriate spacer. Several
of these trioxaquine derivatives (Figure 1) were found to
be extremely potent anti-plasmodial agents [24].
Metabolism and metabolite identification studies
In silico (computational) and in vitro metabolism studies
are primarily aimed at assessing the metabolic stability
of promising hit and lead compounds, and are usually
geared at providing useful information to guide and/or
help in the interpretation of the results from subsequent
pharmacokinetic studies and in vivo assays. In addition,
such information also enables the drug discovery scien-
tists to design and synthesize analogs of the primary
compound(s) that are potentially more stable to metabo-
lism and are likely to have improved oral bioavailability
profiles [25].
However, and probably just as importantly, the in vitro
generation and identification of primary metabolites of a
compound can be an effective way of generating
chemical diversity and augmenting the efforts aimed at
identifying novel active compounds based on an identi-
fied hit. Pharmacologically active metabolites have been
found to contribute significantly to the overall observed
in vivo anti-malarial activity of many compounds. For
example, N-desethylchloroquine, the primary metabolite
of chloroquine, exhibits potent anti-malarial activity
comparable to that of chloroquine [26,27]. This concept
of pharmacologically active metabolites is just as applic-
able to anti-malarial hits derived from natural sources.
Oshima and co-workers [28] reported the isolation and
structural elucidation of two primary metabolites of feb-
rifugine after its incubation for 1 hour at 37°C with
mouse liver S9. Febrifugine is a highly potent anti-
malarial alkaloid isolated from the roots, stem and
leaves of the plant Dichroa febrifuga, a Chinese herb
locally referred to as Chang Shan[29]. One of the major
metabolites designated feb-A (Figure 1) showed extre-
mely potent in vitro anti-plasmodial activity. Isofeb-A
Figure 2 Development of leads from natural products.
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(Figure 1), a synthetic analog of feb-A, was even more
potent than febrifugine in vitro, and had a significantly
higher selectivity index [28].
In addition, metabolism studies may be useful in
understanding the in vivo toxicity of a particular com-
pound; this is because any toxic effects observed after
the administration of a particular compound could be
due to the generation of toxic metabolites. Such infor-
mation derived from metabolism studies would then be
crucial in the design of potent compounds devoid of the
unwanted toxicity of the parent compound. Data from
SAR, toxicity and metabolism studies of febrifugine was
used to design a series of febrifugine analogs with the
aim of identifying compounds with attenuated hepato-
toxicity. This toxicity has precluded the development of
febrifugine as a potential clinical drug, and is mediated
by its arene oxide metabolite (Figure 1). Several analogs
were identified that retained potent anti-plasmodial
activity in vitro but were considerably less cytotoxic
than febrifugine based on an in vitro cytotoxicity assay
on rat hepatocytes. [30,31].
Molecular modeling and docking tools
The use of modern molecular modeling and docking
tools may be applied to enrich the process of derivatiza-
tion of natural products by guiding or complementing
the rational design and selection of more promising
derivatives for subsequent synthesis and biological eva-
luation. An example of such a tool has been developed
and validated for the analysis of artemisinin-based ana-
logs as potential haem inhibitors [32].
Natural product-derived pharmacophores and
template-based virtual screening
Upon the elucidation of the structure of a novel anti-
malarial compound from natural sources, and possibly
informed by preliminary SAR data, it may be possible to
identify its basic pharmacophoric unit(s). This not only
facilitates more elaborate SAR studies, but also allows for
the systematic searches of databases and libraries of
known compounds (from both natural and synthetic
sources) for structural analogs. Analogs identified in this
way can then be acquired/ synthesized and assayed
alongside the primary compound, and thereby provide
additional SAR information and possibly even lead to the
identification of additional active compounds that would
have otherwise remained unidentified. The piperidinyl-
(acetonyl)quinazoline moiety, a structural unit derived
from febrifugine, was used as a template in the search for
analogs in the Walter Reed Army Institute of Research
(WRAIR) Chemical Information System (CIS) database.
In this way, potent analogs of febrifugine were identified
that also had significantly reduced in vitro cytotoxicity
against a variety of mammalian cell lines [33].
Natural product databases
An impressively large number of novel naturally-derived
compounds have been isolated and characterized over
the years. The creation of virtual and/or physical reposi-
tories of these compounds would help to keep track of
these compounds and simultaneously create a rich
resource that can be tapped for drug discovery efforts.
Examples of such databases already exist [34,35], and
these can be valuable for fragment- or ligand-based vir-
tual screening, as well as for ligand docking studies on a
variety of known protein targets. Physical repositories of
crude and purified natural products can provide com-
pound libraries for HTS, metabolic profiling, reverse
pharmacology and related endeavors.
A recent example of the successful application of such
a library of natural products and natural product-like
molecules is in the discovery of highly active anti-malar-
ial spiroindolone compounds. The identification of this
class of compounds began with the screening of about
12,000 pure natural products and synthetic compounds
with structural features found in natural products. Hits
from this initial screen were then filtered based on in
vitro anti-plasmodial activity, cytotoxicity against mam-
malian cells, physicochemical and pharmacokinetic
properties. A compound related to the spiroazepinein-
dole class was thereby identified as a starting point for
medicinal chemistry efforts that eventually led to the
identification of the highly active compound NITD609
(Figure 1). This compound was found to be as effective
as artesunate, showed no evidence of diminished
potency against drug-resistant strains, exhibited favor-
able in vitro solubility and permeability and did not
show cytotoxicity across several human cell lines [36,37].
Physical repositories of natural products, such as the
one set up by the Defense Science and Technology
Organization in Australia, also offer a resource for anti-
malarial screening. Screening of some of the extracts
from this library revealed that some extracts, particularly
those from the Grevillea species, possessed quite strong
anti-plasmodial activity [38].
Target-identification and reverse pharmacology
In addition to serving as a source of anti-malarial lead
compounds, natural products can also add value to
other techniques available for anti-malarial drug discov-
ery. This is particularly with respect to the identification
of new anti-malarial drug targets.
Metabolic profiling offers an exciting approach to the
identification of (oftentimes new) molecular targets of
biologically active molecules, and involves the use of
tools such as NMR [39,40] and Mass spectroscopy
[41,42] in the assessment of the metabolic response of
an organism/cell/parasite following exposure to a bioac-
tive molecule [43]. Bioactive natural products, by virtue
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of their chemical diversity, are particularly suited to act
as probes for the identification of new molecular targets
in this way [43,44]. The metabolic profiling of the
malaria parasite has been reported [39,40,45], which
would suggest the latent potential of this approach.
Another approach by which natural products may be
useful in the identification of druggable targets is
Activity-Based Protein Profiling (ABPP) [46]. Protein-
reactive natural products (or privileged structures
derived from them) can be useful in the development
of ABPP probes [47]. For example, compound E-64, a
cysteine protease inhibitor isolated from cultures of
Aspergillus japonicus[48], is known to interact with
plasmodial cysteine proteases [49] and has been suc-
cessfully applied as a scaffold for the development of
ABPP probes [50]. Proteins/enzymes identified in this
way can then be investigated further as potential thera-
peutic targets by both classical mechanism of action
studies or reverse pharmacology [51].
Reverse pharmacology offers an alternative means by
which the molecular targets of biologically active com-
pounds may be identified. Rather than apply a bioactive
molecule in the identification of a molecular target, reverse
pharmacology begins with the initial identification of
potential protein targets (such as enzymes and receptors)
by the application of bioinformatics tools that exploit the
vast DNA-sequence databases provided by intensive geno-
mic research. The potential targets identified in this way
are then cloned and used to screen candidate ligands,
which may include natural products [52]. As far as anti-
malarial drug discovery is concerned, this approach has
been rendered quite feasible by the successful sequencing
of the genome of the human malaria parasite P. falci-
parum[53], now available as a database for vaccine devel-
opment and drug discovery applications [54].
It has been argued that libraries of natural products
and their derivatives are actually better suited for such
screens simply because they span a much broader che-
mical space than most synthetic compound libraries
currently available for this purpose [55]. It has even
been proposed that screening libraries should be inten-
tionally optimized by adding to them molecules with
biogenic or natural-product-like scaffolds [56], further
underlining the value of natural products to such
strategies.
Conclusion
Natural products may be lead compounds in themselves,
or more likely may serve as hits that may be useful in
providing pharmacophores/templates that can guide the
design of potentially superior analogs and/or the mining
of existing databases of synthetic and semi-synthetic
compounds for previously untested and potentially
active analogs. Promising analogs designed or identified
in this way may be expanded and developed further by
introduction of (bio)isosteric substitutions suggested by
scaffold hopping techniques, or by the application of in
silico (computational) and in vitro profiling of physico-
chemical and ADME(T) parameters to enable the
rational design of potentially improved/superior analogs.
The in vitro generation of metabolites can ably comple-
ment synthetic and semi-synthetic efforts at derivatiza-
tion of primary, naturally derived, bioactive molecules,
thereby broadening the chemical diversity around these
molecules and increasing the likelihood of identifying
promising compounds. Natural products can also find
wide application in target-identification studies - meta-
bolic profiling of the malaria parasite has been reported
and the possible role of natural products acknowledged;
ABPP probes based on scaffolds known to interact with
malarial proteins have been developed; the elucidation
and reporting of the malaria genome affords the oppor-
tunity for reverse pharmacology.
The potential of natural products to provide or inspire
the development of anti-malarial lead compounds is,
therefore, really quite evident. However, to raise the
chances of the actual realization of this potential, it has
become necessary to think beyond the confines of con-
ventional natural-product drug discovery. The applica-
tion of a wide variety of scientific tools and the close
and interactive collaboration of experts in diverse scien-
tific disciplines (such as chemistry, pharmacology, mole-
cular biology and genetics) has become practically
obligatory if these truly multi-disciplinary efforts are to
indeed be successful. The fact that literature on the
application of some of these approaches towards anti-
malarial drug discovery based on natural products is
sparse is indicative of their underutilization in this
regard, a situation that should arguably be addressed.
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